5AM Venture Management
Latest statistics and disclosures from 5AM Venture Management's latest quarterly 13F-HR filing:
- Top 5 stock holdings are TRDA, ELVN, SKYE, Artiva Biotherapeutics, DNTH, and represent 46.29% of 5AM Venture Management's stock portfolio.
- Added to shares of these 4 stocks: Artiva Biotherapeutics (+$36M), EYPT (+$8.0M), CNTA, BHVN.
- Started 1 new stock position in Artiva Biotherapeutics.
- Reduced shares in these 5 stocks: ELVN (-$22M), QTTB, COGT, SKYE, DNTH.
- Sold out of its position in QTTB.
- 5AM Venture Management was a net buyer of stock by $15M.
- 5AM Venture Management has $484M in assets under management (AUM), dropping by 8.26%.
- Central Index Key (CIK): 0001799883
Tip: Access up to 7 years of quarterly data
Positions held by 5AM Venture Management consolidated in one spreadsheet with up to 7 years of data
Download as csv
Download as Excel
Portfolio Holdings for 5AM Venture Management
5AM Venture Management holds 28 positions in its portfolio as reported in the September 2024 quarterly 13F filing
| Company (Ticker) | Portfolio Weight | Valued At | Change in Shares | Share Count | Share Price | |
|---|---|---|---|---|---|---|
| Entrada Therapeutics (TRDA) | 14.6 | $70M | 4.4M | 15.98 |
|
|
| Enliven Therapeutics (ELVN) | 9.2 | $45M | -32% | 1.8M | 25.54 |
|
| Skye Bioscience Com New (SKYE) | 8.0 | $39M | -2% | 9.9M | 3.91 |
|
| Artiva Biotherapeutics | 7.5 | $36M | NEW | 2.4M | 15.45 |
|
| Dianthus Therapeutics (DNTH) | 7.0 | $34M | 1.2M | 27.38 |
|
|
| Biohaven (BHVN) | 4.9 | $24M | 479k | 49.97 |
|
|
| Tyra Biosciences (TYRA) | 4.6 | $22M | 939k | 23.51 |
|
|
| Centessa Pharmaceuticals Sponsored Ads (CNTA) | 4.2 | $21M | +3% | 1.3M | 15.99 |
|
| Tectonic Therapeutic (TECX) | 4.0 | $20M | 647k | 30.30 |
|
|
| Praxis Precision Medicines I Com New (PRAX) | 4.0 | $20M | 340k | 57.54 |
|
|
| Celldex Therapeutics Com New (CLDX) | 3.5 | $17M | 497k | 33.99 |
|
|
| Miragen Therapeutics (VRDN) | 3.5 | $17M | 737k | 22.75 |
|
|
| Viking Therapeutics (VKTX) | 3.1 | $15M | 238k | 63.31 |
|
|
| Pharvaris N V (PHVS) | 3.1 | $15M | 798k | 18.52 |
|
|
| Erasca (ERAS) | 3.0 | $15M | 5.4M | 2.73 |
|
|
| Moonlake Immunotherapeutics Class A Ord (MLTX) | 2.9 | $14M | 282k | 50.42 |
|
|
| Anaptysbio Inc Common (ANAB) | 2.5 | $12M | 358k | 33.50 |
|
|
| Silence Therapeutics Ads (SLN) | 1.8 | $8.7M | 476k | 18.18 |
|
|
| Eyepoint Pharmaceuticals Com New (EYPT) | 1.7 | $8.4M | +2000% | 1.1M | 7.99 |
|
| Cogent Biosciences (COGT) | 1.3 | $6.1M | -28% | 562k | 10.80 |
|
| Scpharmaceuticals (SCPH) | 1.1 | $5.5M | 1.2M | 4.56 |
|
|
| Vor Biopharma (VOR) | 0.9 | $4.5M | 6.4M | 0.70 |
|
|
| Rallybio Corp (RLYB) | 0.9 | $4.2M | 3.6M | 1.17 |
|
|
| Gh Research Ordinary Shares (GHRS) | 0.8 | $3.8M | 573k | 6.69 |
|
|
| Adverum Biotechnologies Com New (ADVM) | 0.8 | $3.8M | 542k | 7.02 |
|
|
| Mersana Therapeutics (MRSN) | 0.5 | $2.5M | 1.3M | 1.89 |
|
|
| Zentalis Pharmaceuticals (ZNTL) | 0.4 | $1.8M | 490k | 3.68 |
|
|
| Cidara Therapeutics Com New (CDTX) | 0.1 | $610k | 57k | 10.75 |
|
Past Filings by 5AM Venture Management
SEC 13F filings are viewable for 5AM Venture Management going back to 2019
- 5AM Venture Management 2024 Q3 filed Nov. 14, 2024
- 5AM Venture Management 2024 Q2 filed Aug. 14, 2024
- 5AM Venture Management 2024 Q1 filed May 15, 2024
- 5AM Venture Management 2023 Q4 filed Feb. 14, 2024
- 5AM Venture Management 2023 Q3 filed Nov. 14, 2023
- 5AM Venture Management 2023 Q2 filed Aug. 14, 2023
- 5AM Venture Management 2023 Q1 filed May 15, 2023
- 5AM Venture Management 2022 Q4 filed Feb. 14, 2023
- 5AM Venture Management 2022 Q3 filed Nov. 14, 2022
- 5AM Venture Management 2022 Q2 filed Aug. 15, 2022
- 5AM Venture Management 2022 Q1 filed May 16, 2022
- 5AM Venture Management 2021 Q4 filed Feb. 3, 2022
- 5AM Venture Management 2021 Q3 filed Nov. 15, 2021
- 5AM Venture Management 2021 Q2 filed Aug. 16, 2021
- 5AM Venture Management 2021 Q1 filed May 17, 2021
- 5AM Venture Management 2020 Q4 filed Feb. 16, 2021